Distributed facility for fragment based drug discovery

基于片段的药物发现的分布式设施

• 批准号: LE160100047
• 负责人: Prof Martin Scanlon
• 金额: $ 25.34万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Infrastructure, Equipment and Facilities
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2016-09-27
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LE160100047
• 关键词: Distributed; facility; fragment; based; drug

Distributed facility for fragment based drug discovery: The facility aims to provide researchers with the ability to generate small molecules that modulate therapeutically and biologically important protein targets. Fragment-based drug design (FBDD) provides a rational approach to generate such biologically active compounds. The facility is designed to allow researchers throughout Australia to access the necessary infrastructure to undertake FBDD projects against a range of biologically important targets. The facility aims to enable access to high-throughput nuclear magnetic resonance spectroscopy and surface plasmon resonance, and to generate the capacity for automation in chemical synthesis and sample preparation to expedite the development of novel bioactive molecules. The development of better approaches to hit development may benefit many researchers in Australia employing FBDD.

用于基于片段的药物发现的分布式设施： 该设施旨在为研究人员提供产生小分子的能力，这些小分子可以调节治疗和生物上重要的蛋白质靶标。基于片段的药物设计(FBDD)为合成此类生物活性化合物提供了一种合理的途径。该设施旨在允许澳大利亚各地的研究人员访问必要的基础设施，以针对一系列具有生物重要性的目标开展FBDD项目。该设施旨在实现高通量核磁共振波谱和表面等离子体共振，并实现化学合成和样品制备的自动化能力，以加快新型生物活性分子的开发。开发更好的HIT开发方法可能会使澳大利亚许多使用FBDD的研究人员受益。